| Literature DB >> 29463254 |
Dharmendra Choudhary1, Priyanka Kothari1, Ashish Kumar Tripathi1, Sonu Singh2, Sulekha Adhikary1, Naseer Ahmad1, Sudhir Kumar3, Kapil Dev3,4, Vijay Kumar Mishra1, Shubha Shukla2, Rakesh Maurya3, Prabhat R Mishra5, Ritu Trivedi6.
Abstract
<span class="abstract_title">BACKGROUND: <span class="Species">Spinacia oleracea is an important dietary vegetable in India and throughout the world and has many beneficial effects. It is cultivated globally. However, its effect on osteoarthritis that mainly targets the cartilage cells remains unknown. In this study we aimed to evaluate the anti-osteoarthritic and chondro-protective effects of SOE on chemically induced osteoarthritis (OA).Entities:
Keywords: Cartilage; Monosodium iodoacetate (MIA); Osteoarthritis (OA); Spinacia oleracea extract (SOE)
Mesh:
Substances:
Year: 2018 PMID: 29463254 PMCID: PMC5819303 DOI: 10.1186/s12906-018-2117-9
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Primer sequences of various rat genes used for qPCR
| Oligo name | Sequence (5’ to 3’) |
|---|---|
|
| F: CAT.GTT.CAG.CTT.TGT.GGA.CCT |
|
| F: TGT.GAT.GAA.AGA.CGG.CAC.AC |
|
| F: AAT.GGG.AGC.CAG.CCT.ACA.C |
|
| F: TGA.AGA.AGG.AGA.GCG.AGG.AA |
|
| F: CAC.AGC.CAT.TTC.GAG.CTT.TT |
|
| F: TGG.ACA.AGC.AGC.TCC.AAA.G |
|
| F: CCT.CTG.CAT.GAA.GAC.GAC.ATA.A |
|
| F: GGT.GAT.ATT.GTG.TTC.GCC.TTC |
|
| F: TGA.ACT.TCG.GGG.TGA.TCG |
|
| F: CAG.CAA.AAG.GCC.TTC.GTA.AA |
|
| F: CCA.GGT.CCT.GCT.GGA.AAA |
|
| F: CCC.CTA.TAT.GCT.CGA.CCT.GT |
|
| F: CGT.TTT.GCA.ATG.CAG.ACG.TA |
|
| F: CCC.GCG.AGT.ACA.ACC.TTC.T |
F Forward Primer, R Reverse Primer
Fig. 1SOE has antioxidant activity and is non-toxic for chondrocytes. a MTT assay at different concentrations of SOE (μg/ml) showed that it is safe and does not impart toxic effects on chondrocyte viability. b Anti-oxidant ability of SOE by DPPH and (c) lipid peroxidation inhibition by MDA assay (D) Free radicals scavenging activity by ABTS assays and (E) GAG release measurement by DMMB assays. All values are expressed as mean ± S.E.M. (n = 6); *P < 0.05; **P < 0.01, ***P < 0.001 compared to control
Fig. 2Effect of SOE on chondrogenic proteins. Western blot analysis of Sox 9 and Col 2 after 3-Methyl-6,7-(methylenedioxy) quercetagetin, and 3-O-Methylpatuletin (active compounds extracted from SOE) is represented after treatment in rat articular chondrocytes isolated from 5 days old pups
Fig. 3Effect of SOE treatment at articular and sub-chondral bone. a Images of excised knee from various groups showed morphological changes in different treated groups. b and c macroscopic photographs of femur and tibia respectively after termination of study. d Radiographic images of various groups and (e) 2D micro-CT images of knees. There was significant cartilage loss and sub-chondral bone parts in MIA-injected group (marked with an arrow). Treatment with SOE ameliorates articular degradation
Fig. 4Histological and dynamic histological analysis of articular cartilage and subchondral bone in experimental groups. a 3D μ-CT images of articular cartilage. b safranin-O staining (c) toluidine blue staining of sagittal sections of tibia. Double headed arrow showing hyaline cartilage and calcified cartilage (d) OARSI score from five different sections n = 3 per group. Micro-CT analysis of sub-chondral bone (e) total tissue volume (TV), (f) bone volume/tissue volume (BV/TV and (g) trabecular porosity (Tb. Pf). All values are expressed as Mean ± S.E.M. (n = 6/group); *P < 0.05, **P < 0.01, ***P < 0.001 compared to the MIA group #P < 0.05, ##P < 0.01, compared to the 250 mg.kg− 1 day− 1 dose, NS= non significant
Fig. 5SOE improves micro-architectural and behavioural parameters. a Representative 3D μCT images of tibia plateau region of different groups. b Trabecular number (Tb.N, 1/mm); (c) Trabecular Separation; (Tb.Sp, mm) (d) Open-field activity and (e) Rota rod test to examine the locomotor function and motor coordination. All values are expressed as Mean ± S.E.M. (n = 6/group); *P < 0.05, **P < 0.01, ***P < 0.001 compared to the MIA group, ###P < 0.001 compared to the 250 mg.kg− 1 day− 1 dose, NS= non significant
Fig. 6SOE inhibits MIA induced pro-inflammatory gene expression. qPCR determination of mRNA levels of pro-inflammatory genes (a) IL1-β, (B) TNF-α, (c) Col-10, (d) MMP-1, (e) MMP-3 and (F) MMP-13 in isolated bone region which contain cartilage and sub-chondral bone. All values are expressed as Mean ± S.E.M. (n = 6/group); *P < 0.05, **P < 0.01, ***P < 0.001 compared to the MIA group #P < 0.05, ##P < 0.01, compared to the 250 mg.kg− 1 day− 1 dose. Interleukin-1 beta (IL-1β), Tumor necrosis factor alpha (TNFα), Collagen type 10 (Col10), Matrix metalloproteinases (MMPs) like interstitial collagenase (MMP-1), stromelysin-1 (MMP-3), and collagenase 3 (MMP-13), NS= non significant
Fig. 7SOE increases MIA inhibited chondrogenic marker gene expression. qPCR determination of mRNA levels of chondrogenic genes (a) Sox9, (b) Bmp2, (c) Col2a, (d) Aggrecan, (e) TIMP-1 and (f) TIMP-2 in isolated bone region which contain cartilage and sub-chondral bone. All values are expressed as Mean ± S.E.M. (n = 6/group); *P < 0.05, **P < 0.01, ***P < 0.001 compared to the MIA group #P < 0.05, ##P < 0.01, compared to the 250 mg.kg− 1 day− 1 dose. Sex determining region Y-box 9 (SOX9) (Fig. 6a), bone morphogenetic protein 2 (BMP2) (Fig. 6b), collagen type-II (Col2) Tissue inhibitors of matrix metalloproteinases (TIMPs), NS= non significant
Fig. 8Effect of SOE on serum and urinary osteoarthritic markers. a Serum GST level measurements b serum COMP measurements and c urinary CTX-II levels. All values are expressed as Mean ± S.E.M. (n = 6/group); *P < 0.05, **P < 0.01, ***P < 0.001 compared to the MIA group compared to the 250 mg.kg− 1 day− 1 dose. GSTs (Glutathione S-transferases), serum COMP (cartilage oligomeric matrix protein) and Urinary CTX-II (C-telopeptide of type II collagen), NS= non significant